Literature DB >> 23250563

[Pain therapy for Fabry's disease].

C Sommer1, N Uçeyler, T Duning, K Arning, R Baron, E Brand, S Canaan-Kühl, M Hilz, D Naleschinski, C Wanner, F Weidemann.   

Abstract

Fabry's disease is an X-chromosome linked lysosomal storage disorder with α-galactosidase A deficiency and subsequent multiple organ involvement. An early and common symptom also in later stages of the disease is pain. This pain depends on various precipitating factors and can severely compromise the quality of life. So-called Fabry crises can lead to the necessity for intensive care treatment. The pain can be classified as predominantly neuropathic and is difficult to treat. In addition, medication has to be adjusted to concomitant cardiac and renal involvement in Fabry's disease. This review gives guidance for pain therapy in Fabry's disease based on the available evidence and on experience.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23250563     DOI: 10.1007/s00108-012-3204-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

Review 1.  Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options.

Authors:  J MacDermot; K D MacDermot
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 3.  Clinical practice. Long-QT syndrome.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

4.  [Intravenous lidocaine as treatment for the painful episodes in Fabry's disease].

Authors:  J M Politei
Journal:  Rev Neurol       Date:  2009 Aug 1-15       Impact factor: 0.870

5.  Small fiber dysfunction predominates in Fabry neuropathy.

Authors:  M Dütsch; H Marthol; B Stemper; M Brys; T Haendl; M J Hilz
Journal:  J Clin Neurophysiol       Date:  2002-12       Impact factor: 2.177

6.  painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain.

Authors:  Rainer Freynhagen; Ralf Baron; Ulrich Gockel; Thomas R Tölle
Journal:  Curr Med Res Opin       Date:  2006-10       Impact factor: 2.580

7.  Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

Authors:  Anette Torvin Møller; Flemming Winther Bach; Ulla Feldt-Rasmussen; Ase Rasmussen; Lis Hasholt; He Lan; Claudia Sommer; Steen Kølvraa; Martin Ballegaard; Troels Staehelin Jensen
Journal:  Pain       Date:  2009-08-07       Impact factor: 6.961

8.  Small fiber neuropathy in female patients with fabry disease.

Authors:  Rocco Liguori; Vitantonio Di Stasi; Enrico Bugiardini; Renzo Mignani; Alessandro Burlina; Walter Borsini; Agostino Baruzzi; Pasquale Montagna; Vincenzo Donadio
Journal:  Muscle Nerve       Date:  2010-03       Impact factor: 3.217

9.  Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.

Authors:  Torquil Watt; Alessandro P Burlina; Chiara Cazzorla; Dorothee Schönfeld; Maryam Banikazemi; Robert J Hopkin; Ana Maria Martins; Katherine Sims; Dana Beitner-Johnson; Fanny O'Brien; Ulla Feldt-Rasmussen
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

10.  Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

Authors:  M Ries; E Mengel; G Kutschke; K S Kim; F Birklein; F Krummenauer; M Beck
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

View more
  2 in total

Review 1.  Pain management strategies for neuropathic pain in Fabry disease--a systematic review.

Authors:  Y Schuller; G E Linthorst; C E M Hollak; I N Van Schaik; M Biegstraaten
Journal:  BMC Neurol       Date:  2016-02-24       Impact factor: 2.474

2.  Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.

Authors:  Juan M Politei; Didier Bouhassira; Dominique P Germain; Cyril Goizet; Antonio Guerrero-Sola; Max J Hilz; Elspeth J Hutton; Amel Karaa; Rocco Liguori; Nurcan Üçeyler; Lonnie K Zeltzer; Alessandro Burlina
Journal:  CNS Neurosci Ther       Date:  2016-03-28       Impact factor: 5.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.